CEO: Rich-Henry Schabowsky, Ph.D., J.D.

Visit Website‍ ‍

EpiVax focuses on developing precision cancer immunotherapies that are customized and specifically designed for each patient's tumors, leveraging the Ancer™ platform and advances in next generation sequencing.  EpiVax was founded by an internationally known woman scientist, and has the potential to make a significant impact in the treatment of all types of solid tumors.